ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.498,38
0,32%
S&P 500
5.187,67
0,00%
Dow Jones
39.056,39
0,44%
Euro vs US Dollar
1,07453
-0,01%
Bitcoin
61.239,35
0,08%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Kanada
  5. NEO
  6. Cybin Inc (CYBN)

  7. Cybin Inc (CYBN) News

CYBN

Cybin (CYBN)

Cybin Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NEO:CYBN
DatumZeitQuelleÜberschriftSymbolFirma
24/03/202213h18InvestorsHub NewsWireCybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting ParticipantsNEO:CYBNCybin Inc
16/03/202214h40InvestorsHub NewsWireCybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022NEO:CYBNCybin Inc
18/02/202214h37InvestorsHub NewsWireCybin Announces Additional Adelia Milestone AchievementNEO:CYBNCybin Inc
15/02/202214h29InvestorsHub NewsWireThe Chopra Foundation Announces Partnership with Cybin Inc. to Increase Education and Awareness of the Potential Use of Psychedelics in Supporting Well-Being and Mental HealthNEO:CYBNCybin Inc
09/02/202214h36InvestorsHub NewsWireCybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety DisordersNEO:CYBNCybin Inc
27/01/202214h35InvestorsHub NewsWireCybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022NEO:CYBNCybin Inc
11/01/202216h08InvestorsHub NewsWireInstitutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the BrainNEO:CYBNCybin Inc
22/12/202114h21InvestorsHub NewsWireCybin Provides 2021 Year End SummaryNEO:CYBNCybin Inc
21/12/202114h57InvestorsHub NewsWireCybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect ConferenceNEO:CYBNCybin Inc
15/12/202115h44InvestorsHub NewsWireCybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety DisordersNEO:CYBNCybin Inc
08/12/202117h11InvestorsHub NewsWireCybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use DisorderNEO:CYBNCybin Inc
30/11/202116h07InvestorsHub NewsWireCybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related DistressNEO:CYBNCybin Inc
15/11/202114h31InvestorsHub NewsWireCybin Inc. Reports its Second Quarter Financial Results and Recent Business HighlightsNEO:CYBNCybin Inc
08/11/202114h29InvestorsHub NewsWireCybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental HealthNEO:CYBNCybin Inc
04/11/202112h46InvestorsHub NewsWireCybin Granted DEA Schedule I Manufacturing LicenseNEO:CYBNCybin Inc
02/11/202114h13InvestorsHub NewsWireCybin Hosting Research and Development Briefing on November 8, 2021NEO:CYBNCybin Inc
26/10/202115h44InvestorsHub NewsWireCybin Announces FDA Investigational New Drug Authorization of Cybin's Sponsored Feasibility Study Using Kernel Flow TechnologyNEO:CYBNCybin Inc
12/10/202115h23InvestorsHub NewsWireCybin Files an International Patent Application Covering Psychedelic Delivery MethodsNEO:CYBNCybin Inc
19/08/202116h34InvestorsHub NewsWireCybin Files Two Additional International Patent Applications in Support of the Company's Research Phase ProgramsNEO:CYBNCybin Inc
04/08/202116h00InvestorsHub NewsWireCybin to Commence Trading on the NYSE American on August 5NEO:CYBNCybin Inc
22/07/202115h41InvestorsHub NewsWireCybin Announces Conditional Listing Approval from NYSE AmericanNEO:CYBNCybin Inc
13/07/202114h23InvestorsHub NewsWireCybin Files its 13th Patent Application and Announces Digital Therapeutics StrategyNEO:CYBNCybin Inc
06/07/202113h21InvestorsHub NewsWireCybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental Health Centers of ExcellenceNEO:CYBNCybin Inc
24/06/202115h42InvestorsHub NewsWireCybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory BoardNEO:CYBNCybin Inc
22/06/202115h39InvestorsHub NewsWireCybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule StudyNEO:CYBNCybin Inc
16/06/202116h44InvestorsHub NewsWireCybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004NEO:CYBNCybin Inc
08/06/202113h16InvestorsHub NewsWireCybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout andNEO:CYBNCybin Inc
 Showing the most relevant articles for your search:NEO:CYBN

Kürzlich von Ihnen besucht

AMEX
XLE
Energy Select Sector SPDR
NYSE
DIS
Walt Disney
NYSE
KO
Coca Cola
AMEX
XLV
Health Care Select Sector
NYSE
MCD
McDonalds
PM
XAUUSD
Gold vs US Dollar
TG
LHA
Deutsche Lufthansa
TG
D7G
Nel ASA
CCOM
US100
US Tech 100
NASDAQ
GOOGL
Alphabet
FX
EURJPY
Euro vs Yen
NASDAQ
QQQ
Invesco QQQ Trust Series 1
TG
BAS
BASF
AMEX
SPY
SPDR S&P 500
TG
BAYN
Bayer
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten